Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Colorectal Cancer Reports
Published in: Current Colorectal Cancer Reports 1/2022

01-02-2022 | Interventional Radiology | Surgery and Surgical Innovations in Colorectal Cancer (M Al-Kasspooles, Section Editor)

Liver-Directed Therapy for Metastatic Colon Cancer: Update

Authors: John J. Waddell, Patricia H. Townsend, Zachary S. Collins, Carissa Walter

Published in: Current Colorectal Cancer Reports | Issue 1/2022

Login to get access

Abstract

Purpose of Review

To discuss the emerging technologies in the field of Interventional radiology (IR) for the management of metastatic colorectal cancer (mCRC). We review the field of selective internal radiation therapy (SIRT), and well-known IR treatments, with a more focused investigation of radioembolization with Yttrium-90 (Y-90).

Recent Findings

State-of-the-art treatment modalities for unresectable hepatic malignancies are crucial to increased patient survival. There are many options for the treating physician to manage and potentially cure patient’s disease, with Y-90 as the cornerstone of liver neoplasm treatment. Additionally, current research in the fields of dosimetry and radiomics may allow for more optimized patient specific radiation doses.

Summary

Continued advancements in colorectal surgery and interventional radiology have improved survival outcomes for patients with mCRC. Current treatment options are numerous and often include partial hepatectomy and SIRT. We review current literature and discuss our experiences in treating patients with advanced liver malignancies.
Literature
1.
Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669–85.PubMedCrossRef
2.
Tan HL, Lee M, Vellayappan BA, Neo WT, Yong WP. The role of liver-directed therapy in metastatic colorectal cancer. Curr Colorectal Cancer Rep. 2018;14(5):129–37.PubMedPubMedCentralCrossRef
3.
4.
Li J, Wei X, Liu Y, Cui B. Prognostic significance of distant metastasis location in patients with metastatic colorectal cancers. Int J Clin Exp Med. 2016;9(11):21681–9.
5.
Gabriela Chiorean E, Nandakumar G, Fadelu T, Temin S, Alarcon-Rozas AE, Bejarano S, et al. Treatment of patients with late-stage colorectal cancer: ASCO resource-stratified guideline. J Global Oncol. 2020;6:414–38.CrossRef
6.
Swaid F, Tsung A. Current management of liver metastasis from colorectal cancer. Curr Colorectal Cancer Rep. 2018;14(1):12–21.CrossRef
7.
Abedi P, Bayat A, Ghasemzadeh S, Raad M, Pashaiefar H, Ahmadvand M Upregulation of miR-410 is linked with unfavorable prognosis in patients with colorectal cancer. British journal of biomedical science. 2020
8.
Bi F, Wang Q, Dong Q, Wang Y, Zhang L, Zhang J. Circulating tumor DNA in colorectal cancer: opportunities and challenges. Am J Transl Res. 2020;12(3):1044–55.PubMedPubMedCentral
9.
Chee B, Ibrahim F, Esquivel M, Van Seventer EE, Jarnagin JX, Zhang L, Ju JH, Price KS, Raymond VM, Corvera CU, Hirose K, Nakakura EK, Van Loon K, Corcoran RB, Parikh AR, Atreya CE. Circulating tumor derived cell-free DNA (ctDNA) to predict recurrence of metastatic colorectral cancer (mCRC) following curative intent surgery or radiation. J Clin Oncol. 2021;39(15):3562–5.
10.
Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, Wang W, Sheng H, Pu H, Mo H, Zuo Z, Liu Z, Li C, Xie C, Zeng Z, Li W, Hao X, Liu Y, Cao S, Liu W, Gibson S, Zhang K, Xu G, Xu RH Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci transl Med. 2020;12(524).
11.
Silva-Fisher JM, Dang HX, White NM, Strand MS, Krasnick BA, Rozycki EB et al. Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression. Nature Communications. 2020;11(1).
12.
Shang P, Gao R, Zhu Y, Zhang X, Wang Y, Guo M, et al. VEGFR2-targeted antibody fused with IFNαmut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity. Acta Pharm Sin B. 2021;11(2):420–33.PubMedCrossRef
13.
Taïeb J, André T, El Hajbi F, Barbier E, Toullec C, Kim S, et al. Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: the SAMCO-PRODIGE 54 randomised phase II trial. Dig Liver Dis. 2021;53(3):318–23.PubMedCrossRef
14.•
Deschamps F, Ronot M, Gelli M, Durand-Labrunie J, Tazdait M, Hollebecque A, et al. Interventional radiology for colorectal liver metastases. Curr Colorectal Cancer Rep. 2020;16(2):29–37. Review of current IR treatments for mCRC.CrossRef
15.
Van Tilborg AAJM, Meijerink MR, Sietses C, Van Waesberghe JHTM, Mackintosh MO, Meijer S, et al. Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: A potentially curative intervention. Br J Radiol. 2011;84(1002):556–65.PubMedPubMedCentralCrossRef
16.
Song P, Sheng L, Sun Y, An Y, Guo Y, Zhang Y. The clinical utility and outcomes of microwave ablation for colorectal cancer liver metastases. Oncotarget. 2017;8(31):51792–9.PubMedPubMedCentralCrossRef
17.
James T, Hill J, Fahrbach T, Collins Z. Differences in radiation activity between glass and resin 90y microspheres in treating unresectable hepatic cancer. Health Phys. 2017;112(3):300–4.PubMedCrossRef
18.
Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiol. 2011;259(3):641–57.CrossRef
19.
Memon K, Lewandowski RJ, Kulik L, Riaz A, Mulcahy MF, Salem R. Radioembolization for primary and metastatic liver cancer. Semin Radiat Oncol. 2011;21(4):294–302.PubMedPubMedCentralCrossRef
20.
Molvar C, Lewandowski RJ. Intra-arterial therapies for liver masses Data Distilled. Radiol Clin North Am. 2015;53(5):973–84.PubMedCrossRef
21.
Sacco R, Mismas V, Marceglia S, Romano A, Giacomelli L, Bertini M, et al. Transarterial radioembolization for hepatocellular carcinoma: an update and perspectives. World J Gastroenterol. 2015;21(21):6518–25.PubMedPubMedCentralCrossRef
22.
Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109–22.PubMedCrossRef
23.
Ibrahim SM, Lewandowski RJ, Sato KT, Gates VL, Kulik L, Mulcahy MF, et al. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol. 2008;14(11):1664–9.PubMedPubMedCentralCrossRef
24.
25.•
Salem R, Lewandowski R, Roberts C, Goin J, Thurston K, Abouljoud M, et al. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol. 2004;15(4):335–45. Trial demonstrating glass microspheres safety in unresectable HCC patients with portal vein thrombosis.PubMedCrossRef
26.
Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterol. 2016;151(6):1155-63.e2.CrossRef
27.
Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–36.PubMedCrossRef
28.
Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913–21.PubMedCrossRef
29.
Ricke J, Sangro B, Amthauer H, Bargellini I, Bartenstein P, De Toni E, et al. The impact of combining selective internal radiation therapy (SIRT) with sorafenib on overall survival in patients with advanced hepatocellular carcinoma: the soramic trial palliative cohort. J Hepatol. 2018;68:S102.CrossRef
30.
Van Hazel GA, Heinemann V, Sharma NK, Findlay MPN, Ricke J, Peeters M, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2016;34(15):1723–31.PubMedCrossRef
31.
Khatib J, Kainthla R. Optimal use of FOLFOXIRI plus bevacizumab as first-line systemic treatment in metastatic colorectal cancer. Curr Colorectal Cancer Rep. 2020;16(4):89–95.CrossRef
32.•
Core JM, Frey GT, Sharma A, Bussone ST, Legout JD, McKinney JM, et al. Increasing yttrium-90 dose conformality using proximal radioembolization enabled by distal angiosomal truncation for the treatment of hepatic malignancy. J Vasc Interv Radiol. 2020;31(6):934–42. Use of voxel-based dosimetry in Y90 treatment.PubMedCrossRef
33.
Morán V, Prieto E, Sancho L, Rodríguez-Fraile M, Soria L, Zubiria A et al. Impact of the dosimetry approach on the resulting 90Y radioembolization planned absorbed doses based on 99mTc-MAA SPECT-CT: is there agreement between dosimetry methods? EJNMMI Physics. 2020;7(1)
34.
Skanjeti A, Magand N, Defez D, Tordo J, Rode A, Manichon AF et al. Selective internal radiation therapy of hepatic tumors: morphologic and functional imaging for voxel-based computer-aided dosimetry. Biomed Pharm. 2020;132.
35.
Ahmadzadehfar H, Sabet A, Biermann K, Muckle M, Brockmann H, Kuhl C, et al. The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. J Nucl Med. 2010;51(8):1206–12.PubMedCrossRef
36.
Abbott E, Young RS, Hale C, Mitchell K, Falzone N, Vallis KA et al. Stereotactic inverse dose planning after yttrium-90 selective internal radiation therapy in hepatocellular cancer. Adv Rad Oncol. 2021;6(2).
37.
38.
Kafrouni M, Allimant C, Fourcade M, Vauclin S, Delicque J, Ilonca AD, et al. Retrospective voxel-based dosimetry for assessing the ability of the body-surface-area model to predict delivered dose and radioembolization outcome. J Nucl Med. 2018;59(8):1289–95.PubMedCrossRef
39.
Haverkamp BT, Pedersen WR, Hunt S, Walter C, Hill JD, Collins ZC. Tumor response time to progression and progression-free survival in glass versus resin radioembolization of hepatocellular cancer. J Vasc Int Radiol. 2017;28(2):e22.
40.
Ibrahim SM, Nikolaidis P, Miller FH, Lewandowski RJ, Ryu RK, Sato KT, et al. Radiologic findings following Y90 radioembolization for primary liver malignancies. Abdom Imaging. 2009;34(5):566–81.PubMedCrossRef
41.
Kennedy AS, Salem R. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. Cancer J. 2010;16(2):163–75.PubMedCrossRef
42.
DeBacker SJJ, Vavricek J, Iqbal S, Hunt SL et al. Retrospective review of survival outcomes in glass and resin Y-90 microsphere treatment of hepatic malignancies. J Int Radiol Nucl Med. 2018:1–9.
43.
Chiesa C, Mira M, Maccauro M, Romito R, Spreafico C, Sposito C, et al. A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with90Y glass microspheres. Q J Nucl Med Mol Imaging. 2012;56(6):503–8.PubMed
44.
Kunam V, Shrikanthan S, Srinivas S. Radiation dosimetry of glass versus resin Y-90 microsphere radioembolization in patients with colorectal liver metastases. J Nucl Med. 2012;53(supplement 1):1203.
45.
Vente MAD, Wondergem M, van der Tweel I, van den Bosch MAAJ, Zonnenberg BA, Lam MGEH, et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol. 2009;19(4):951–9.PubMedCrossRef
46.
Biederman DM, Titano JJ, Bishay VL, Durrani RJ, Dayan E, Tabori N, et al. Radiation segmentectomy versus Tace combined with microwave ablation for unresectable solitary hepatocellular carcinoma up to 3 cm: a propensity score matching study. Radiol. 2017;283(3):895–905.CrossRef
47.
PMA approval for TheraSphere™, 21 CFR 814.39(a)(7) (2021).
48.
Medical S. A Prospective, multicenter, open-label single arm study evaluating the safety & efficacy of selective internal radiation therapy using SIR-spheres® Y-90 resin microspheres on DoR & ORR in unresectable hepatocellular carcinoma patients clinicaltrials.gov2021 [updated March 23, 2021.
49.
Rizzo S, Botta F, Raimondi S, Origgi D, Fanciullo C, Morganti AG, et al. Radiomics: the facts and the challenges of image analysis. Eur Radiol Exp. 2018;2(1):36.PubMedPubMedCentralCrossRef
50.
Creasy JM, Cunanan KM, Chakraborty J, McAuliffe JC, Chou J, Gonen M, et al. Differences in liver parenchyma are measurable with CT radiomics at initial colon resection in patients that develop hepatic metastases from stage II/III colon cancer. Ann Surg Oncol. 2021;28(4):1982–9.PubMedCrossRef
51.
Wei L, Cui C, Xu J, Kaza R, El Naqa I, Dewaraja YK. Tumor response prediction in 90Y radioembolization with PET-based radiomics features and absorbed dose metrics. EJNMMI Physics. 2020;7(1).
52.
Eisenhauer EA, Verweij J. New response evaluation criteria in solid tumors: RECIST guideline version 1.1. Eur J Cancer. 2009;7(2–3):5.CrossRef
53.•
Dohan A, Gallix B, Guiu B, Le Malicot K, Reinhold C, Soyer P, et al. Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. Gut. 2020;69(3):531–9. Evaluated the use of radiomics to predict outcomes in patients with mCRC.PubMedCrossRef
54.•
Shur J, Orton M, Connor A, Fischer S, Moulton CA, Gallinger S, et al. A clinical-radiomic model for improved prognostication of surgical candidates with colorectal liver metastases. J Surg Oncol. 2020;121(2):357–64. Association between clinical features, radiomic features and a combined CRM based on medical imaging.CrossRef
55.
Saini A, Wallace A, Alzubaidi S, Knuttinen MG, Naidu S, Sheth R et al. History and evolution of Yttrium-90 radioembolization for hepatocellular carcinoma. J Clin Med. 2019;8(1).
Metadata
Title
Liver-Directed Therapy for Metastatic Colon Cancer: Update
Authors
John J. Waddell
Patricia H. Townsend
Zachary S. Collins
Carissa Walter
Publication date
01-02-2022
Publisher
Springer US
Published in
Current Colorectal Cancer Reports / Issue 1/2022
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-022-00474-1
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits